Abstract: The present invention concerns a method for detecting aggregate-forming circulating protein forms in a biological sample of human origin that may contain said aggregate-forming circulating protein forms, characterized in that it uses a non-protein agent I producing aggregation of the circulating forms of the noninfectious proteins involved in pathological aggregation processes of the central nervous system and/or a non-protein agent II for capturing the natural aggregrates of aggregate-forming circulating protein forms or the aggregates induced by said agents I.

Abstract: Oligonucleotides used to prime in vitro nucleic acid amplification of 16S rRNA sequences or DNA encoding 16S rRNA sequences for many species within the genus Mycobacterium are disclosed. Kits including such oligonucleotides are disclosed. Methods of detecting Mycobacterium species using the oligonucleotides in in vitro nucleic acid amplification are disclosed.

Abstract: The present invention concerns a method for detecting aggregate-forming circulating protein forms in a biological sample of human origin that may contain said aggregate-forming circulating protein forms, characterized in that it uses a non-protein agent I producing aggregation of the circulating forms of the noninfectious proteins involved in pathological aggregation processes of the central nervous system and/or a non-protein agent II for capturing the natural aggregrates of aggregate-forming circulating protein forms or the aggregates induced by said agents I.

Abstract: Oligonucleotides used to prime in vitro nucleic acid amplification of 16S rRNA sequences or DNA encoding 16S rRNA sequences for many species within the genus Mycobacterium are disclosed. Kits including such oligonucleotides are disclosed. Methods of detecting Mycobacterium species using the oligonucleotides in in vitro nucleic acid amplification are disclosed.

Abstract: The present invention is directed to novel nucleotide sequences to be used for diagnosis, identification of the strain, typing of the strain and giving orientation to its potential degree of virulence, infectivity and/or latency for all infectious diseases more particularly tuberculosis. The present invention also includes method for the identification and selection of polymorphisms associated with the virulence' and/or infectivity in infectious diseases more particularly in tuberculosis by a comparative genomic analysis of the sequences of different clinical isolates/strains of infectious organisms. The regions of polymorphisms, can also act as potential drug targets and vaccine targets. More particularly, the invention also relates to identifying virulence factors of M. tuberculosis strains and other infectious organisms to be included in a diagnostic DNA chip allowing identification of the strain, typing of the strain and finally giving orientation to its potential degree of virulence.

Abstract: Oligonucleotides used to prime in vitro nucleic acid amplification of 16S rRNA sequences or DNA encoding 16S rRNA sequences for many species within the genus Mycobacterium are disclosed. Kits including such oligonucleotides are disclosed. Methods of detecting Mycobacterium species using the oligonucleotides in in vitro nucleic acid amplification are disclosed.

Abstract: Oligonucleotides used to prime in vitro nucleic acid amplification of 16S rRNA sequences or DNA encoding 16S rRNA sequences for many species within the genus Mycobacterium are disclosed. Kits including such oligonucleotides are disclosed. Methods of detecting Mycobacterium species using the oligonucleotides in in vitro nucleic acid amplification are disclosed.

Abstract: A method for aqueous phase nucleic acid isolation from a sample, comprising a step of nucleic acid adsorption on a particulate substrate, is disclosed. The method comprises an adsorption reagent preparation step (a) that includes a sol consisting of a aqueous continuous phase and a dispersed particulate substrate phase including a functionalized particulate polymer prepared by polymerizing (1) a first water-soluble acrylamide or acrylamide derivative monomer, (2) at least one cross-linking agent and (3) at least one second water-soluble, cationic and functional monomer, said polymer having a predetermined lower critical solubility temperature (LCST) of 25-45° C.

Abstract: Methods of detecting Mycobacterium species using oligonucleotides to amplify in vitro 16S rRNA sequences or DNA encoding 16S rRNA sequences for many species in the genus Mycobacterium are disclosed. Amplification oligonucleotides for in vitro amplification of 16S rRNA sequences or DNA encoding 16S rRNA sequences from many Mycobacterium species are disclosed. Kits containing oligonucleotides useful for in vitro amplification of 16S rRNA sequences or DNA encoding 16S rRNA sequences from many Mycobacterium species are disclosed.

Abstract: Methods of detecting Mycobacterium species using oligonucleotides to amplify in vitro 16S rRNA sequences or DNA encoding 16S rRNA sequences for many species in the genus Mycobacterium are disclosed. Amplification oligonucleotides for in vitro amplification of 16S rRNA sequences or DNA encoding 16S rRNA sequences from many Mycobacterium species are disclosed. Kits containing oligonucleotides useful for in vitro amplification of 16S rRNA sequences or DNA encoding 16S rRNA sequences from many Mycobacterium species are disclosed.